Abstract
Metastasis remains one of the major challenges before hepatocellular carcinoma (HCC) is finally conquered. This paper summarized a decade’s studies on HCC metastasis at the Liver Cancer Institute of Fudan University. We have established a stepwise metastatic human HCC model system, which included a metastatic HCC model in nude mice (LCI-D20), a HCC cell line with high metastatic potential (MHCC97), a relatively low metastatic potential cell clone (MHCC97L) and several stepwise high metastatic potential cell clones (MHCC97H, HCCLM3, and HCCLM6) from their parent MHCC97 cell. Endeavors have been made for searching human HCC metastasis-related chromosomes/proteins/genes. Monogene-based studies revealed that HCC invasion/metastasis was similar to that of other solid tumors, and the biological characteristics of small HCC were only slightly better than that of large HCC. Using comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), genotyping, cDNA microarray, and 2-dimensional gel electrophoresis, we obtained some interesting results. In particular, in collaboration with the National Institute of Health (NIH) in the United States, we generated a molecular signature that can classify metastatic HCC patients, identified osteopontin as a lead gene in the signature, and found that genes favoring metastasis progression were initiated in the primary tumors. We also found that chromosome 8p deletion, particularly in the region of 8p23, was associated with HCC metastasis. Cytokeratin 19 was identified as one of the proteins, which was found in MHCC97H, but not in MHCC97L cells. Experimental interventions using the high metastatic nude mice model have provided clues for the prevention of HCC metastasis. Translation from workbench to bedside demonstrated that serum VEGF, microvessel density, and p53 scoring may be of value for the prediction of postoperative metastatic recurrence. Interferon alpha proved effective for the prevention of recurrence both experimentally and clinically. In conclusion, HCC metastasis that probably initiated in the primary tumor is a multigene-involved, multistep, and changing process. The further elucidation of the mechanism underlying HCC metastasis will provide a more solid basis for the prediction and prevention of the metastatic recurrence of HCC.
Similar content being viewed by others
References
Aruga A, Takasaki K, Hanyu F (1993) Establishment and characterization of liver metastatic model of human hepatoma in nude mice. Int Hepatol Commun 1:138–145
Bu W, Huang XW, Tang ZY (1997) The role of MMP-2 in the invasion and metastasis of hepatocellular carcinoma. Zhonghua Yixue Zazhi (Natl Med J China) 77:661–664 (Chin)
Bu W, Tang ZY, Sun FX, Ye SL, Liu KD, Xue Q, Chen J, Gao DM (1998) Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepato-Gastroenterol 45:1056–1061
Clark EA, Golub TR, Lander ES, et al (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535
Collonge-Rame MA, Bresson-Hadni S, Koch S, Carbillet JP, Blagosklonova O, Mantion G, Miguet JP, Heyd B, Bresson JL (2001) Pattern of chromosomal imbalances in non-B virus related hepatocellular carcinoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 127:49–52
Eisenhauer EA (2003) From the molecule to the clinic- Inhibiting HER2 to treat breast cancer (editorial) N Engl J Med 344:841–842
He B, Tang ZY, Liu KD, Zhou G (1996) Analysis of the cellular origin of hepatocellular carcinoma by p53 genotype. J Cancer Res Clin Oncol 122:763–766
He B, Liu YK, Tang ZY, Xue Q (1997) Gene mutation and expression in metastatic model of human hepatocellular carcinoma in nude mice established by orthotopic implantation. Zhonghua Ganzangbing Zazhi (Chin J Hepatol) 5:245–245 (Chin)
Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M (2002) alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 35:853–860
Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228–232
Jemal A, Thomas A, Murray T, Thum M (2002) Cancer statistics, 2002. CA Cancer J Clin 52:23–47
Ji XN, Ye SL, Li Y, Tian B, Chen J, Gao DM, Bao WH, Liu YK, Tang ZY (2003) Contribution of lung tissue extracts to invasion and migration of human hepatocellular carcinoma cells with various metastatic potentials. J Cancer Res Clin Oncol 129:556–564
Jiang XP, Liu KD, Zhou XD, Tang ZY, Zhang ZF, Zhang Y, Wu XF (1994) Identification of a new human nm23 gene, nm 23-H3b. Chin J Cancer Res 6:18–23
Jin F, Xiang YB, Gao YT (1998) Cancer survival in Shanghai, People’s Republic of China. In: Sankaranaryanan R, Black RJ, Parkin DM (eds) Cancer survival in developing countries. IARC Scientific Publication No. 145. IARC, Lyon, pp. 37–50
Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Doi T, Endo H, Yamashita T, Okada Y (1998a) Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 33:376–382
Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Endo H, Doi T, Mandai K, Ishitsuka H (1998b) Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients. Cancer 82:1260–1267
Kim J, Kim SH, Lee SU, Ha GH, Kang DG, Ha NY, Ahn JS, Cho HY, Kang SJ, Lee YJ, Hong SC, Ha WS, Bae JM, Lee CW, Kim JW (2002) Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrixassisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis 23:4142–4156
Kitay-Cohen Y, Amiel A, Ashur Y, Fejgin MD, Herishanu Y, Afanasyev F, Bomstein Y, Lishner M (2001) Analysis of chromosomal aberrations in large hepatocellular carcinomas by comparative genomic hybridization. Cancer Genet Cytogenet 131:60–64
Kobayashi T, Kubota K, Takayama T, Makuuchi M (2001) Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 181:284–288
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H (2002) Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89:418–422
Kusano N, Okita K, Shirahashi H, Harada T, Shiraishi K, Oga A, Kawauchi S, Furuya T, Sasaki K (2002) Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer 94:746–751
Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, Chan AT, Yeo W, Mok TS, Yu SC, Leung NW, Johnson PJ (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797–801
Li XM, Tang ZY, Zhou G, Liu YK, Ye SL (1998a) Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17:13–17
Li XM, Tang ZY, Xue Q, Liu YK, Ye SL, Zhang XR, Zhao ZH (1998b) Suramin inhibits growth and metastasis of human hepatocellular cacinoma in nude mice. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 15:3–4 (Chin)
Li XM, Tang ZY, Chen FG (1998c) Gene transfer of dominant-negative flk-1 mutant inhibits angiogenesis, growth and metastases of human hepatocellular carcinoma in nude mice. Zhongguo Zhongliu Shengwu Zhiliao Zazhi (Chin J Cancer Biother) 5:160–162 (Chin)
Li XM, Sun HC, Tang ZY, Zhou J (1999a) Cytostatic calcium influx inhibitor carboxyamido- triazole inhibited angiogenesis induced by human hepatocellular carcinoma. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 16:489–490 (Chin)
Li XM, Tang ZY, Qin LX, Zhou J, Sun HC (1999b) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellula rcarcinoma. J Exp Clin Cancer Res 18:511–517
Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7:630–636
Li Y, Tang ZY, Ye SL, Liu BB, Liu YK, Chen J, Xue Q (2003) Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129:43–51
Liang XH, Loncarevic IF, Tang ZY, Yu YQ, Zentgraf H, Schroder CH (1991) Resection of hepatocellular carcinoma: Oligocentric origin of recurrent and multinodular tumours. J Gastroenterol Hepatol 6:77–80
Liao Y, Tang ZY, Ye SL, Liu KD, Sun FX, Huang Z (2000) Modulation of apoptosis, tumorigenesity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20. Hepatogastroenterology 47:365–370
Liu H, Ye SL, Yang J, Tang ZY, Liu YK, Qin LX, Qiu SJ, Sun RX (2002) The microcell mediated transfer of human chromosome 8 into highly metastatic rat liver cancer cell line C5F. World J Gastroenterol 9:449–453
Liu H, Ye SL, Li WC, LiY, Liu YK, Qin LX, Qiu SJ, Sun RX, Chen J, Tang ZY (2003) Quantitative analysis of expression of TEY1 gene in liver cancer cells with different metastatic potential. Ai Zheng (Chin J Cancer) 22:561–565 (Chin)
Liu YK, Li Y, Ma XM, Chen J, Xue Q, Gao DM, Zhang Y, Ye SL, Tang ZY (2002) Regulation of liver cancer related gene and alpha fetal protein expression by cell differentiation agent II. Zhongguo Zhongliu 11:169–172 (Chin)
Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW, Leng XS, Chen WF (2002) Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 86:110–116
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–56
Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334:1561–1567
Muto Y, Moriwaki H, Saito A (1999) Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340:1046–1047
Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LH (2000a) Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol 6:565–568
Niu Q, Tang ZY, Chen L, Ma ZC, Qin LX, Zhang LH (2000b) Basic fibroblast growth factor is a potential predictive marker of metastatic recurrence after resection of hepatocellular carcinoma. Zhonghua Waike Zazhi (Chin J Surg) 38:637–639 (Chin)
Niu Q, Tang ZY, Ma ZC, Qin LX, Bao WH, Zhang LH (2001) Relationship between serum matrix metalloproteinase-2 and metastasis and recurrence following radical hepatic resection in hepatocellular carcinoma. Zhonghua Ganzangbing Zazhi (Chin J Hepatol) 9:56–58 (Chin)
Okochi O, Hibi K, Uemura T, Inoue S, Takeda S, Kaneko T, Nakao A (2002) Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res 8:2875–2878
Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N (2001) Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: meta-analysis of three randomized controlled trials. Cancer 91:2378–2385
Pan H-W, Ou Y-H, Peng S-Y, Liu S-H, Lai P-L, Lee P-H, Sheu J-C, Chen C-L, Hsu H-C (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119–127
Parasole R, Izzo F, Perrone F, Pignata S, Galati MG, Leonardi E, Castiglione F, Orlando R, Castello G, Esposito G, Gallo C, Daniele B (2001) Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Cancer Res 7:3504–3509
Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimsating the world cancer burden: globocan 2000. Int J Cancer 94:153–156
Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J (2001a) Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233:227–235
Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J (2001b) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298–304
Qin LX, Tang ZY, Liu KD, Ye SL, Zhou G (1995) p53 mutations may be related to tumor invasiveness of human hepatocellular carcinoma in China. Oncol Rep 2:1175–1179
Qin LX, Tang ZY, Liu KD, Ye SL, He B, Zhang Y, Zhou G (1996) Alterations of CDKN2 (P16/MTS1) exon 2 in human hepatocellular carcinoma. Oncol Rep 3:405–408
Qin LX, Tang ZY, Sham JST, Ma ZC, Ye SL, Zhou XD, Wu ZQ, Trent JM, Guan XY (1999) The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res 59:5662–5665
Qin LX, Tang ZY, Ye SL, Liu YK, Ma ZC, Zhou XD, Wu ZQ, Lin ZY, Sun FX, Tian J, Guan X-Y, Pack SD, Zhuang ZP (2001) Chromosome 8p deletion is associate with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared. J Cancer Res Clin Oncol 127:482–488
Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, Yuan J, Huang LW, Jia HL, Sun HC, Wang L (2002a) P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 8:459–463
Qin LX, Tang ZY (2002b) The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 8:385–392
Qiu SJ, Ye SL, Wu ZQ, Tang ZY, Liu YK (1998) The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J Cancer Res Clin Oncol 124:253–258
Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A (1999) Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 79:604–610
Schwartz JD, Schwartz M, Mandeli J, Sung M (2002) Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3:593–603
Seki S, Kitada T, Kawada N, Sakaguchi H, Kadoya H, Nakatani K, Satake K, Kuroki T (1999) Establishment and characteristics of human hepatocellular carcinoma cells with metastasis to lymph nodes. Hepatogastroenterology 46:2812–2817
Seow TK, Liang RC, Leow CK, Chung MC (2001) Hepatocellular carcinoma: from bedside to proteomics. Proteomics 1:1249–1263
Shao DM, Wang QH, Chen C, Shen ZH, Yao M, Zhou XD, Tang ZY, Gu JX (1999) N-Actylglucosaminyltransferase V activity in metastatic models of human hepatocellular carcinoma in nude mice. J Exp Clin Cancer Res 18:331–335
Steeg PS (2003) Angiogenesis inhibitors: motivator of metastasis? Nature Med 9:822–823
Sun FX, Tang ZY, Liu KD, Ye SL, Xue Q, Gao DM, Ma ZC (1996) Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 66:239–243
Sun HC, Tang ZY, Zhou G, Li XM (1998) Kai-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases. J Exp Clin Cancer Res 17:307–311
Sun HC, Li XM, Xue Q, Chen J, Gao DM, Tang ZY (1999a) Study of angiogenesis induced by metastatic and non-metastatic liver cancer by corneal micropocket model in nude mice. World J Gastroenterol 5:116–118
Sun HC, Zhang M, Tang ZY, Li XM, Wang L, Gao DM, Xue Q, Chen J (1999b) Inhibition of growth of LCI D20 hepatocellular carcinoma by Endostatin. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 116:491–492 (Chin)
Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC (1999c) Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol, 125:419–426
Sun HC, Tang ZY (2003) Preventive treatments for recurrence after curative resection of hepatocellular carcinoma—a literature review of randomized control trials. World J Gastroenterol 9:635–640
Sun JJ, Zhou XD, Liu YK, Tang ZY, Feng JX, Zhou G, Xue Q, Chen J (1999) Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1. J Cancer Res Clin Oncol 125:28–34
Sun JJ, Zhou XD, Liu YK, Tang ZY, Sun RX, Zhao Y, Uemura T (2000) Inhibitory effects of syntheticβpeptide on invasion and metastasis of liver cancer. J Cancer Res Clin Oncol 126:595–600
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807
Tang ZY (1989) Small hepatocellular carcinoma. In: Tang ZY, Wu MC, Xia SS (eds) Primary liver cancer. Berlin, Springer, pp. 191–203
Tang ZY (2003) Thirty years’ studies on surgery and related basic research of hepatocellular carcinoma. Ann Coll Surg HK 7:11–17
Tang ZY, Ma ZC (1989) Establishment of transplantable human hepatocellular carcinoma in nude mice and their use in studies of tumor markers and radioimmunodetection. In: Tang ZY Wu MC, Xia SS (eds) Primary liver cancer. Berlin, Springer, pp. 172–179
Tang ZY, Yu YQ, Zhou XD (1984) An important approach to prolonging survival further after radical resection of AFP positive hepatocellular carcinoma. J Exp Clin Cancer Res 3:359–366
Tang ZY, Qin LX, Wang XM, Zhou G, Liao Y, Weng Y, Jiang XP, Lin ZY, Liu KD, Ye SL (1998) Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J 111:313–318
Tang ZY, Zhou XD, Lin ZY, Yang BH, Ma ZC, Ye SL, Wu ZQ, Fan J, Liu YK, Liu KD, Qin LX, Tian J, Sun HC, He B, Xia JL, Qiu SJ, Zhou J (1999) Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis. Chin Med J 112:887–891
Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q (1999) New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expression of the factors associated with metastasis. Br J Cancer 81:814–821
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton M, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards AR (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009
Wang G, Zhao Y, Liu X, Wang L, Wu C, Zhang W, Liu W, Zhang P, Cong W, Zhu Y, Zhang L, Chen S, Wan D, Zhao X, Huang W, Gu J (2001) Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes Cancer 31:221–227
Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL (2000a) High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32:43–48
Wang L, Tang ZY, Xue Q, Sun HC, Chen J, Zhang XR, Zhao ZH, Gao DM, Liu YK, Ye SL (2000b) Effect of interferon-α and all-trans retinoic acid on recurrence and metastasis of hepatocellular carcinoma. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 17:421–423 (Chin)
Wang XM, Tang ZY, Xue Q, Hong XY, Bao WH, Zou HQ (1995) Transforming growth factor α induces proliferation and expression of epidermal growth factor receptor in hepatocellular carcinoma cells. J Exp Clin Cancer Res 14:179–184
Witzigmann H, Geissler F, Benedix F, Thiery J, Uhlmann D, Tannapfel A, Wittekind C, Hauss J (2002) Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. Surgery 131:34–43
Wong CM, Lee JM, Lau TC, Fan ST, Ng IO (2002) Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res 8:2266–2272
Wong IH, Lau WY, Leung T, Yeo W, Johnson PJ (1999) Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: a quantitative analysis. Clin Cancer Res 5:4021–4027
Wu XF, Fan J, Lin ZY, Wu ZQ, Lu JZ, Zhou J, Tang ZY (2003) Quantitative analysis of AFP m RNA in portal, hepatic and peripheral venous blood of patients with HCC during liver surgery and its clinical significance. Zhonghua Gandan Waike Zazhi (Chin J Hepatobiliary Surg) 9:338–341 (Chin)
Xia JL, Yang BH, Tang ZY, Sun FX, Xue Q, Gao DM (1997) Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J Cancer Res Clin Oncol 123:383–387
Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, Cheng ZH, Li NG, Du JJ, Hu W, Shen KT, Lu G, Fu G, Zhong M, Xu SH, Gu WY, Huang W, Zhao XT, Hu GX, Gu JR, Chen Z, Han ZG (2001) Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 98:15089–15094
Yang J, Qin LX, Ye SL, Liu YK, Li Y, Gao DM, Chen J, Tang ZY (2003) The abnormalities of chromosome 8 in two hepatocellular carcinoma cell lines with the same genetic background and different metastatic potential. J Cancer Res Clin Oncol 129:303–308
Yao M, Zhou XD, Zha XL, Shi DR, Fu J, He JY, Lu HF, Tang ZY (1997) Expression of the integrin α5 subunit and its mediated cell adhesion in hepatocellular carcinoma. J Cancer Res Clin Oncol 123:435–440
Yao M, Zhou DP, Jiang SM, Wang QH, Zhou XD, Tang ZY, Gu JX (1998a) Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J Cancer Res Clin Oncol 124:27–30
Yao M, Zhou XD, Liu YK, Tang ZY (1998b) Expression of E-cadherin in hepatocellular carcinoma with high invasiveness. Zhonghua Xiaohua Zazhi (Chin J Digest) 18:31–33 (Chin)
Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen YD, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nature Med 9:416–423
Ye YJ, Yu YQ, Tang ZY, Wan DF, Lu JZ, He LP (1998) Construction of nm23-H1 cDNA clone and the relationship between its mRNA expression and metastasis in hepatocellular carcinoma. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 15:17–18 (Chin)
Zhang LH, Qin LX, Ma ZC, Ye SL, Liu YK, Ye QH, Wu X, Huang W, Tang ZY (2003) Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genomic microsatellite analysis. J Cancer Res Clin Oncol 129:279–286
Zhao X, Li J, He Y, Lan F, Fu L, Guo J, Zhao R, Ye Y, He M, Chong W, Chen J, Zhang L, Yang N, Xu B, Wu M, Wan D, Gu J (2001) A novel growth suppressor gene on chromosome 17p13.3 with a high frequency of mutation in human hepatocellular carcinoma. Cancer Res 61:7383–7387
Zhao X, He M, Wan D, Ye Y, He Y, Han L, Guo M, Huang Y, Qin W, Wang MW, Chong W, Chen J, Zhang L, Yang N, Xu B, Wu M, Zuo L, Gu J (2003) The minimum LOH region defined on chromosome 17p13.3 in human hepatocellular carcinoma with gene content analysis. Cancer Lett 190:221–232
Zheng Q, Tang ZY, Xue Q (1998a) Changes of PAI-1 and biological behaviour of human hepatocellular carcinoma in metastatic model of nude mice. Zhonghua Waike Zazhi (Chin J Surg) 36:687–689 (Chin)
Zheng Q, Tang ZY, Xue Q (1998b) Role of heparin on tumor growth and metastasis in model of human hepatocellular carcinoma in nude mice. Zhonghua Ganzangbing Zazhi (Chin J Hepatol) 6:151–152 (Chin)
Zheng Q, Tang ZY, Wu ZQ (1999) Changes of PAI-1 in plasma and tumor extract of patients with hepatocellular carcinoma. Zhonghua Xiaohua Zazhi (Chin J Digest) 19:16–18 (Chin)
Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB (2000) Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 126:641–646
Zheng XY, Lin ZY, Tang ZY, Liu YK, Feng XL, Zhuang W (1998) The abundance of NM23-H1 mRNA is related with in situ microenvironment and intrahepatic metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 17:337–341
Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SL (2000a) Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 126:57–61
Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Wang L, Bao WH, Qiu SJ (2000b) Study on inhibition of the growth and metastasis of LCID20 hepatocellular carcinoma by capecitabine. Zhonghua Shiyan Waike Zazhi (Chin J Exp Surg) 17:403–405 (Chin)
Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Ye SL (2001) The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma. J Cancer Res Clin Oncol 127:559–564
Acknowledgments
We thank Fan-Xian Sun, Jian Tian, Qiong Xue, and Jie Chen for the establishment of metastatic models; Qi Zheng, Xiao-Ming Li, Qi Niu, and Xiao-Feng Wu for studies of metastatic predictors; Ming Yao and Lian-Hai Zhang for studies on metastasis-related genes and chromosomes; Yong Liao and Jing-Jing Sun for experimental interventions. These studies were supported in part by the State Key Basic Research Program of China (G1998051211), Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, and the Fund for Leading Specialty of Shanghai Metropolitan Bureau of Health 983001.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tang, ZY., Ye, SL., Liu, YK. et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 130, 187–196 (2004). https://doi.org/10.1007/s00432-003-0511-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-003-0511-1